Results 11 to 20 of about 115,857 (253)
Genetics of Myeloproliferative Neoplasms. [PDF]
Hematology/Oncology Clinics of North America, 2021 Myeloproliferative neoplasms are hematopoietic stem cell disorders based on somatic mutations in JAK2, calreticulin, or MPL activating JAK-STAT signaling.
Meyer, Sara C., Szybinski, Jakub
core +4 more sources
Myelodysplastic/myeloproliferative neoplasms
Seminars in Diagnostic Pathology, 2011 According to the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues, myelodysplastic/myeloproliferative neoplasms are clonal myeloid neoplasms that have some clinical, laboratory, or morphologic findings that ...
CAZZOLA, MARIO +5 more
core +6 more sources
Molecular biology of Philadelphia-negative myeloproliferative neoplasms
Revista Brasileira de Hematologia e Hemoterapia, 2012 Myeloproliferative neoplasms are clonal diseases of hematopoietic stem cells characterized by myeloid hyperplasia and increased risk of developing acute myeloid leukemia.
Paulo Vidal Campregher +3 more
doaj +2 more sources
Journal of Bone Marrow Transplantation and Cellular Therapy, 2021 In addition to the chronic myeloid leukemia (CML) BCR-ABL1+, classic myeloproliferative neoplasms include polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Neysimelia Costa Villela +5 more
doaj +2 more sources
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms
Haematologica, 2011 Background Myeloproliferative neoplasms constitute a group of diverse chronic myeloid malignancies that share pathogenic features such as acquired mutations in the JAK2, TET2, CBL and MPL genes.
Damla Olcaydu +10 more
doaj +2 more sources
Philadelphia-negative chronic myeloproliferative neoplasms [PDF]
Revista Brasileira de Hematologia e Hemoterapia, 2012 Chronic myeloproliferative diseases without the Philadelphia chromosome marker (Ph-), although first described 60 years ago, only became the subject of interest after the turn of the millennium.
Rosane Isabel Bittencourt +7 more
doaj +4 more sources
Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation [PDF]
Hematology, Transfusion and Cell Therapy, 2018 Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms.
Maira da Costa Cacemiro +11 more
doaj +2 more sources
Clinicopathologic Characteristics of Somatic TP53 Mutations in Philadelphia Chromosome–Negative Myeloproliferative Neoplasms: A Systematic Review [PDF]
eJHaem, Volume 7, Issue 5, October 2026.ABSTRACT Background TP53 mutations (TP53m) are uncommon in chronic‐phase Ph–negative myeloproliferative neoplasms but become enriched in myelofibrosis (MF) and accelerated/blast phase myeloproliferative (AP/BP‐MPN). Their prevalence, allelic distribution, and phase‐stratified outcomes have not been systematically synthesized.
Mahmood Aldapt +9 more
wiley +2 more sources
The Microenvironment in Myeloproliferative Neoplasms [PDF]
Hematology/Oncology Clinics of North America, 2021 Chronic inflammation is a hallmark of myeloproliferative neoplasms (MPNs), with elevated levels of proinflammatory cytokines being commonly found in all 3 subtypes. Systemic inflammation is responsible for the constitutional symptoms, thrombosis risk, premature atherosclerosis, and disease evolution in MPN.
Ramanathan, Gajalakshmi +1 more
openaire +3 more sources